Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
-
Brazil's Lula vetoes law reducing Bolsonaro's sentence
-
Macron accuses US of 'turning away' from allies, breaking rules
-
Joshua pays tribute to close friends killed in crash
-
Protesters, US law enforcement clash after immigration officer kills woman
-
French ex-spy chief cops suspended jail term for 15 mn euro shakedown
-
Syria bombs Kurdish areas in city of Aleppo
-
Confusion reigns over Venezuela's oil industry as US looms
-
Stocks retrench as traders eye geopolitics, US jobs data
-
US trade gap shrinks to smallest since 2009 as imports fall
-
Russia releases French researcher in prisoner exchange
-
Spain signs agreement with Church to compensate abuse victims
-
Macron accuses US of 'breaking free from international rules'
-
US could run Venezuela, tap its oil for years, Trump says
-
England to stick with Stokes and McCullum despite Ashes flop
-
Nobel laureate Bialiatski tells AFP 'important' to keep pressure on Belarus
-
Russia slams Western peacekeeping plan for Ukraine
-
Bordeaux's Du Preez wary of Northampton's Champions Cup revenge mission
-
Romero apologises for Spurs slump as crisis deepens
-
Former Premier League referee Coote gets suspended sentence for indecent image
-
New clashes hit Iran as opposition urges protests, strikes
-
Stocks retreat as traders eye geopolitics, US jobs data
-
'Girl with a Pearl Earring' to be shown in Japan, in rare trip abroad
-
Syria tells civilians to leave Aleppo's Kurdish areas
-
'Sign of life': defence boom lifts German factory orders
-
Japan's Fast Retailing raises profit forecast after China growth
-
Olympic champion Zheng out of Australian Open
-
England's Brook 'deeply sorry' for nightclub fracas
-
New clashes in Iran as opposition urges more protests
-
Equity markets mostly down as traders eye US jobs data
-
England cricket board launches immediate review into Ashes debacle
-
Dancing isn't enough: industry pushes for practical robots
-
Asian markets mostly down as traders eye US jobs data
-
Australia to hold royal commission inquiry into Bondi Beach shooting
-
Sabalenka accuses tour chiefs over 'insane' tennis schedule
-
Cambodia to liquidate bank founded by accused scam boss
-
Farmers enter Paris on tractors in protest at trade deal
-
Viral 'Chinese Trump' wins laughs on both sides of Pacific
-
Stokes vows to stay on but 'wrongs to put right' after crushing Ashes defeat
-
Lidl to drop broadcast TV ads in France
-
Stokes admits 'wrongs to put right' after crushing Ashes defeat
-
Sabalenka impresses again in Australian Open warm-up, vows more to come
-
Gilgeous-Alexander to the rescue as Thunder sink Jazz in overtime
-
From Diaz to 'Mazadona' - five new faces starring at AFCON
-
Startups go public in litmus test for Chinese AI
-
Death of Bazball: Five things we learned from Ashes series
-
Australia's emotional Khawaja bows out for final time with Ashes win
-
Asian markets mixed as traders eye US jobs data
-
Australia win final Test to complete 4-1 Ashes triumph over England
-
Trump withdraws US from key climate treaty, deepening global pullback
-
Trump pulls US out of key climate treaty, deepening global pullback
NYSE - LSE
| RYCEF | 0.29% | 17.05 | $ | |
| CMSC | -0.11% | 22.975 | $ | |
| RBGPF | -0.27% | 81.57 | $ | |
| NGG | -0.05% | 79.35 | $ | |
| GSK | 0.27% | 50.755 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| RELX | 0.61% | 42.44 | $ | |
| AZN | -0.03% | 95.13 | $ | |
| BTI | 1.23% | 53.955 | $ | |
| CMSD | -0.25% | 23.542 | $ | |
| BP | -0.7% | 33.435 | $ | |
| BCC | 5.38% | 77.65 | $ | |
| BCE | 1.73% | 23.74 | $ | |
| JRI | 0.62% | 13.725 | $ | |
| VOD | -0.98% | 13.84 | $ | |
| RIO | -1.93% | 83.27 | $ |
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026
Format: Company Presentation
Day/Time: Tuesday, January 13 at 8:15 AM PST
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
[email protected]
Media Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
L.Miller--AMWN